{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:16:41Z","timestamp":1788322601544,"version":"build-2803163510"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality worldwide. Patients with rheumatoid arthritis (RA) face unique challenges during the pandemic, including concerns regarding infection risk, drug shortages, limited access to care, social isolation, and mental health. This review will examine the multifaceted impacts of the COVID-19 pandemic on patients living with RA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In patients with RA, risk factors for severe COVID-19 outcomes include older age and comorbidities, similar to those in the general population. Glucocorticoids, but not other classes of disease-modifying antirheumatic drugs (DMARDs), appear to be associated with a higher risk of severe COVID-19 outcomes. RA patients have been affected by changes in access to care, telemedicine, drug shortages, anxiety, and social isolation, which may contribute to disease flares.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Glucocorticoids, but not other DMARDs, are associated with a higher risk of severe COVID-19 outcomes in RA patients. Further studies are needed to explore the impact of specific DMARDs on COVID-19 outcomes, understand the broader implications of the COVID-19 pandemic on RA disease activity, and optimize the use of telemedicine in RA management.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000786","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T05:34:22Z","timestamp":1614404062000},"page":"255-261","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":47,"title":["COVID-19 and rheumatoid arthritis"],"prefix":"10.1097","volume":"33","author":[{"given":"Kristin M.","family":"D'Silva","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital"},{"name":"Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary S.","family":"Wallace","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital"},{"name":"Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/acr2.11148","article-title":"Experiences of patients with rheumatic diseases in the US during early days of the COVID-19 pandemic","volume":"2","author":"Michaud","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/annrheumdis-2020-217627","article-title":"Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China","volume":"79","author":"Ye","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/annrheumdis-2020-217888","article-title":"Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a United States \u2018hot spot\u2019","volume":"79","author":"D'Silva","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"R6-20250526","article-title":"Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6\u200amonths into the pandemic","author":"Serling-Boyd","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R7-20250526","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis","author":"Akiyama","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R8-20250526","article-title":"Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R9-20250526","article-title":"COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases (SARDs) compared to the general population: a US Multi-Center Comparative Cohort Study","author":"D'Silva","year":"2020","journal-title":"Arthritis Rheum"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/1744666X.2020.1792778","article-title":"Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19","volume":"16","author":"Sattui","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"R11-20250526","first-page":"1","article-title":"Mitigating the wider health effects of covid-19 pandemic response","volume":"369","author":"Douglas","year":"2020","journal-title":"BMJ"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2020.102523","article-title":"COVID-19 infection and rheumatoid arthritis: faraway, so close!","volume":"19","author":"Favalli","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ard.2010.128637","article-title":"High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis","volume":"70","author":"Au","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.semarthrit.2020.07.007","article-title":"Acute respiratory viral adverse events during use of antirheumatic disease therapies: a scoping review","volume":"50","author":"Kilian","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/annrheumdis-2020-217494","article-title":"COVID-19 and rheumatology: first steps towards a different future?","volume":"79","author":"McInnes","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R17-20250526","article-title":"Dexamethasone in hospitalized patients with COVID-19: preliminary report","author":"Horby","year":"2020","journal-title":"N Engl J Med"},{"key":"R18-20250526","article-title":"Baricitinib plus Remdesivir for hospitalized adults with COVID-19","author":"Kalil","year":"2020","journal-title":"N Engl J Med"},{"key":"R19-20250526","article-title":"Rheumatic disease and COVID-19: epidemiology and outcomes","author":"Hyrich","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMc2009567","article-title":"Covid-19 in immune-mediated inflammatory diseases \u2013 case series from New York","volume":"383","author":"Haberman","year":"2020","journal-title":"N Engl J Med"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/annrheumdis-2020-217424","article-title":"Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies","volume":"79","author":"Monti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R22-20250526","article-title":"What is the true incidence of COVID-19 in patients with rheumatic diseases?","author":"Favalli","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2020.102575","article-title":"SARS-CoV-2 infection among patients with systemic autoimmune diseases","volume":"19","author":"Emmi","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.semarthrit.2020.05.001","article-title":"Incidence of COVID-19 in a cohort of adult and pediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying antirheumatic drugs","volume":"50","author":"Michelena","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R25-20250526","article-title":"COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs","author":"Conticini","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R26-20250526","article-title":"Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study","author":"Jorge","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/acr.22039","article-title":"The risk of venous thromboembolism in patients with rheumatoid arthritis","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/art.40574","article-title":"The lung in rheumatoid arthritis: Focus on interstitial lung disease","volume":"70","author":"Spagnolo","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1164\/rccm.202007-2794OC","article-title":"Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study","volume":"202","author":"Drake","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R30-20250526","article-title":"Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study","author":"Pablos","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cell.2020.08.025","article-title":"Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19","volume":"183","author":"Kaneko","year":"2020","journal-title":"Cell"},{"key":"R33-20250526","first-page":"e1","article-title":"American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 2","volume":"72","author":"Mikuls","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R34-20250526","first-page":"1","article-title":"Tocilizumab in patients hospitalized with COVID-19 pneumonia","volume":"0","author":"Salama","year":"2020","journal-title":"N Engl J Med"},{"key":"R35-20250526","doi-asserted-by":"crossref","DOI":"10.1007\/s11420-020-09798-w","article-title":"Rheumatic disease-related symptoms during the height of the COVID-19 pandemic","author":"Mancuso","year":"2020","journal-title":"HSS J"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2665-9913(20)30286-1","article-title":"Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population","volume":"2","author":"Hooijberg","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/acr.24257","article-title":"Capturing patient-reported outcomes during the COVID-19 pandemic: development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey","volume":"72","author":"Sirotich","year":"2020","journal-title":"Arthritis Care Res"},{"key":"R38-20250526","article-title":"Antimalarial drug shortages during the COVID-19 pandemic: results from the Global Rheumatology Alliance Patient Experience Survey","author":"Sirotich","year":"2020","journal-title":"Am Coll Rheumatol Converg; Virtual"},{"key":"R39-20250526","article-title":"Adaptation of American College of Rheumatology rheumatoid arthritis disease activity and functional status measures for telehealth visits","author":"England","year":"2020","journal-title":"Arthritis Care Res"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41584-020-0449-6","article-title":"Adopting PROs in virtual and outpatient management of RA","volume":"16","author":"Taylor","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"R41-20250526","article-title":"Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries","author":"Dejaco","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:19:45Z","timestamp":1748294385000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000786","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]}}}